PORTFOLIO NEWS Revolution Medicines Presents Data from its SHP2 and Oncogenic RAS(ON) Programs at 6th AACR-IASLC International Joint Conference January 13, 2020 Read More » Nurix Therapeutics and Sanofi Establish Strategic Collaboration to Develop Novel Targeted Protein Degradation Therapies January 6, 2020 Read More » Arcus Biosciences, in Collaboration with Genentech, Announces Two Randomized Clinical Studies to Advance AB928, a Dual Adenosine Receptor Antagonist, into Novel Combinations for Colorectal and Pancreatic Cancers December 18, 2019 Read More » Constellation Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares December 13, 2019 Read More » Gritstone Oncology Reports Promising Early Immunogenicity Activity and Safety Data from its Phase 1 Studies Evaluating its Neoantigen-based Immunotherapies, GRANITE and SLATE December 12, 2019 Read More » RAPT Therapeutics Report Third Quarter 2019 Financial Results and Recent Highlights December 11, 2019 Read More » Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock December 10, 2019 Read More » Constellation Pharmaceuticals Provides Updated Preliminary Data from MANIFEST Clinical Trial with CPI-0610 in Oral and Poster Presentations at ASH December 9, 2019 Read More » RAPT Therapeutics Appoints Rodney Young As Chief Financial Officer December 4, 2019 Read More » Gritstone Oncology Reports Third Quarter 2019 Financial Results and Recent Highlights November 12, 2019 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Revolution Medicines Presents Data from its SHP2 and Oncogenic RAS(ON) Programs at 6th AACR-IASLC International Joint Conference January 13, 2020 Read More »
Nurix Therapeutics and Sanofi Establish Strategic Collaboration to Develop Novel Targeted Protein Degradation Therapies January 6, 2020 Read More »
Arcus Biosciences, in Collaboration with Genentech, Announces Two Randomized Clinical Studies to Advance AB928, a Dual Adenosine Receptor Antagonist, into Novel Combinations for Colorectal and Pancreatic Cancers December 18, 2019 Read More »
Constellation Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares December 13, 2019 Read More »
Gritstone Oncology Reports Promising Early Immunogenicity Activity and Safety Data from its Phase 1 Studies Evaluating its Neoantigen-based Immunotherapies, GRANITE and SLATE December 12, 2019 Read More »
RAPT Therapeutics Report Third Quarter 2019 Financial Results and Recent Highlights December 11, 2019 Read More »
Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock December 10, 2019 Read More »
Constellation Pharmaceuticals Provides Updated Preliminary Data from MANIFEST Clinical Trial with CPI-0610 in Oral and Poster Presentations at ASH December 9, 2019 Read More »
Gritstone Oncology Reports Third Quarter 2019 Financial Results and Recent Highlights November 12, 2019 Read More »
